Department of Medical Affairs & Pharmacovigilance • Clinical Formulary Monograph
D 92/6 Okhla Phase 1, New Delhi, 110020, India • Medical Helpline: +91 11-47532297 • Email: contact@vrmedhealthcare.com
Tremasine
Centrally Acting Opioid & Analgesic-Antipyretic Combination
Tremasine
Centrally Acting Opioid & Analgesic-Antipyretic Combination
Paracetamol IP 325mg + Tramadol Hydrochloride IP 37.5mg
Product Clinical Overview
Tremasine is a fixed-dose analgesic combination of Tramadol Hydrochloride, a centrally acting synthetic opioid with monoaminergic activity, and Paracetamol, a non-salicylate analgesic-antipyretic. The combination provides rapid-onset and sustained relief in moderate to severe acute pain. Schedule H1 prescription drug.
More Images
Actual Tremasine packaging, label panels and blister strip.
Key Ingredients & Pharmacological Profiles
Active chemical constituents, standardized strengths, and physiological roles.
Central prostaglandin synthesis inhibitor providing rapid analgesic and antipyretic action.
Weak µ-opioid agonist with serotonin and noradrenaline reuptake inhibition.
Approved Clinical Indications
Clinical contexts where this formulation is prescribed under medical supervision.
Pharmacological Mechanism of Action
Tramadol binds to µ-opioid receptors and inhibits neuronal reuptake of serotonin and noradrenaline, modulating descending pain pathways. Paracetamol inhibits central cyclo-oxygenase activity, raising the pain threshold and acting on hypothalamic thermoregulation.
Formulation & Delivery Technology
- Complementary fast onset (paracetamol) and sustained action (tramadol)
- Lower individual doses than either agent used alone
- Schedule H1 — for severe acute pain for a period not exceeding 5 days
VR Med Healthcare Pvt. Ltd.
Registered Office & Facility:D 92/6 Okhla Phase 1, New Delhi, 110020, India
Quality Certifications:WHO-GMP Compliant & ISO 9001:2015 Certified
Medical Helpline:+91 11-47532297
Corporate Email:contact@vrmedhealthcare.com
Administration & Packaging Details
As directed by the Physician. Not to exceed 5 days of use. Tablet should be swallowed whole, not chewed or crushed.
10 x 10 Tablets (Blister Strip)
Store in a cool, dry and dark place, below 25°C. Protect from direct sunlight. Do not freeze.
This formulation monograph is published strictly for the professional scientific reference and educational use of Registered Medical Practitioners, Hospitals, and Clinical Laboratories. The technical and pharmacological details presented herein do not constitute medical advice, diagnostic opinion, or therapeutic claims. These products must be prescribed, dispensed, and administered strictly in accordance with local drug regulations and under the supervision of a licensed physician. VR Med Healthcare Pvt. Ltd. does not promote self-medication, off-label usage, or unsolicited consumer health claims.
More in Pain & Muscle
Etoversa-MR
Targeted COX-2 Inhibitor & Spasmolytic Muscle Relaxant
Etoversa-60
Selective COX-2 Inhibitor for Joint & Musculoskeletal Pain
Vibanuron
Pregabalin with Methylcobalamin Neuropathic Pain Formulation
Enhancing Lives With
Quality Healthcare & Integrity.
VR Med Healthcare has been a trusted benchmark in the Indian pharmaceutical sector since 2010. Headquartered in Okhla Phase 1, New Delhi, our dedicated team of over 100 professionals collaborates with leading physicians and distributors across India to make premium medicines accessible and reliable.
“Our goal is to deliver quality of care in a courteous, respectful, and compassionate manner. We hope you will allow us to care for you and strive to be the first and best choice for healthcare professionals and families.”
Kamal Choudhary
Managing Director, VR Med Healthcare
Established
Approved Formulations
Healthcare Specialists
Manufacturing Standard